It really depends on how many pans there are in the fire at the time. If we're partnered with 2055 and/or announced GSO phase I and/or launched 9200 w or w/o a partner all will make a difference.
You worry too much.
Not in CERS now, Bird-- I sold a lot of my non-IDRA positions during yesterday's rally. I'm reducing/getting off margin. I'm so excited about IDRA that I do NOT want to be forced to sell any IDRA shares if the market goes bad for a while...
A guy named Amani has the most shares of IDRA, I think. I'm close to him, then Eduardo.
Nonetheless, it's NOTHING compared to one private investor in CYTR. He's a Florida surgeon who has 100% of his net worth invested in CYTR. He's well known on their message board--and his ownership percentage of the company is so high that it is required SEC public information. His initials are SBP. He is NOT an officer of the company and has no affiliiation with it. He's putting it all on the line!!
The shares are getting locked up, and the tradeable float is decreasing. It shows in the volume.
They are begrudgingly having to bid our stock price up to acquire their shares, and that includes short covering purchases also...
There's a critical subgroup of Lymphoma patients with Kras mutation that PCYC's drug will NOT be effective for, that theoretically, 8400 targets head-on....so we have an unmet need for 8400 in this group, if successful
Critial trial results for XOMA's EYEGUARD trial (for Behcet's Uveitis) is due to be released ANY DAY now...
Since you're an optometrist, you gotta put a few $$$ into it, for sentimental reasons!!
Take a little plunge for the team.
Don't know, Minnesota... I'm not a T.A. expert. They could easily trade FOMX down, since there's a quiet period now before phase 3. However, it's such an obvious buyout target, and with the float being so low, my guess is that institutions are entering their initial positions now, which could increase the price to $12 just like that..
...that we received orphan drug status and that our prominent CEO joined and bought $800K stock after early safety and efficacy of 8400 are likely known in the lower dose cohorts in the OPEN-LABEL WM trial. That's all you need to know for now.
Hey MGM....I must say that it's really nice having a CEO who has $800K in the game at $4 per share, same price as BB when they raised cash last year. Everyone has stake in seeing a floor at $4... So maybe a 50 cent downside risk (barring market collapse of unforeseen event), and upside potential of, say $15 to $150. Sounds good